

Venezuelan Equine Encephalitis Virus, TC-83

Catalog No. NR-63

(Derived from ATCC® VR-1249™)

For research use only. Not for use in humans.

Contributor:

ATCC®

Manufacturer:

BEI Resources

Product Description:

Virus Classification: *Togaviridae, Alphavirus*

Species: Venezuelan equine encephalitis virus

Strain/Isolate: TC-83

Subtype/Serotype: IA/B¹

Original Source: Derived from the original Trinidad donkey strain by serial passage in fetal guinea pig heart cells.^{2,3}

Comments: Venezuelan equine encephalitis virus (VEEV), TC-83 is an attenuated strain of VEEV that was deposited at ATCC® by the National Institutes of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, USA. In-house sequencing confirms that the A3G reversion is absent, excluding this strain from select agent status. The complete genomic sequence of Venezuelan equine encephalitis virus, TC-83 has been sequenced (GenBank: [MZ399799](https://www.ncbi.nlm.nih.gov/nuccore/MZ399799)).^{4,5}

Material Provided:

Each vial contains approximately 1 mL of cell lysate and supernatant from *Chlorocebus* (formerly *Cercopithecus*) *aethiops* kidney epithelial cells infected with Venezuelan equine encephalitis virus, TC-83.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:

NR-63 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Host: *Chlorocebus* (formerly *Cercopithecus*) *aethiops* kidney epithelial cells (Vero; ATCC® CCL-81™)

Growth Medium: Eagle's Minimum Essential Medium containing Earle's Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate and 1.5 g/L of sodium bicarbonate supplemented with 2% fetal bovine serum, or equivalent

Infection: Cells should be 80% to 90% confluent

Incubation: 6 to 8 days at 37°C and 5% CO₂

Cytopathic Effect: Cell rounding and cell lysis

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Venezuelan Equine Encephalitis Virus, TC-83, NR-63."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.

This publication recommends that all persons working in or entering laboratory or animal care areas where activities with Venezuelan equine encephalitis virus are being conducted should have documented evidence of satisfactory vaccination.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Weaver, S. C., et al. "Genetic Evidence for the Origins of Venezuelan Equine Encephalitis Virus Subtype IAB Outbreaks." Am. J. Trop. Med. Hyg. 60 (1999): 441–448. PubMed: 10466974.
2. Randall, R. and J. W. Mills. "Fatal Encephalitis in Man Due to the Venezuelan Virus of Equine Encephalomyelitis in Trinidad." Science 99 (1944): 225–226. PubMed: 17844380.
3. Berge, T. O., I. S. Banks, and W. D. Tigertt. "Attenuation of Venezuelan Equine Encephalomyelitis Virus by *In Vitro* Cultivation in Guinea-Pig Heart Cells." Am. J. Hyg. 73 (1961): 209–218.
4. Johnson, B. J., R. M. Kinney, C. L. Kost, and D. W. Trent. "Molecular Determinants of Alphavirus Neurovirulence: Nucleotide and Deduced Protein Sequence Changes During Attenuation of Venezuelan Equine Encephalitis Virus." J. Gen. Virol. 67 (1986): 1951–1960. PubMed: 3755750. GenBank: L01443.
5. Kinney, R. M., et al. "The Full-Length Nucleotide Sequences of the Virulent Trinidad Donkey Strain of Venezuelan Equine Encephalitis Virus and Its Attenuated Vaccine Derivative, Strain TC-83." Virology 170 (1989): 19–30. PubMed: 2524126. GenBank: L01443.
6. Kinney, R. M., et al. "Attenuation of Venezuelan Equine Encephalitis Virus Strain TC-83 is Encoded by the 5'-Noncoding Region and the E2 Envelope Glycoprotein." J. Virol. 67 (1993): 1269–1277. PubMed: 7679745.
7. Paessler, S., et al. "Replication and Clearance of Venezuelan Equine Encephalitis Virus from the Brains of Animals Vaccinated with Chimeric SIN/VEE Viruses." J. Virol. 80 (2006): 2784–2796. PubMed: 16501087.
8. Rao, V., M. E. Hinz, B. A. Roberts, and D. Fine. "Environmental Hazard Assessment of Venezuelan Equine Encephalitis Virus Vaccine Candidate Strain V3526." Vaccine 22 (2004): 2667–2673. PubMed: 15193393.
9. Paessler S., et al. "Recombinant Sindbis/Venezuelan Equine Encephalitis Virus is Highly Attenuated and Immunogenic." J. Virol. 77 (2003): 9278–9286. PubMed: 12915543.
10. Ludwig, G. V., et al. "Comparative Neurovirulence of Attenuated and Non-Attenuated Strains of Venezuelan Equine Encephalitis Virus in Mice." Am. J. Trop. Med. Hyg. 64 (2001): 49–55. PubMed: 11425162.
11. Smith, D. R., et al. "Venezuelan Equine Encephalitis Virus Transmission and Effect on Pathogenesis." Emerg. Infect. Dis. 12 (2006): 1190–1196. PubMed: 16965696.
12. Anishchenko, M., et al. "Venezuelan Encephalitis Emergence Mediated by a Phylogenetically Predicted Viral Mutation." Proc. Natl. Acad. Sci. USA 103 (2006): 4994–4999. PubMed: 16549790

ATCC® is a trademark of the American Type Culture Collection.

